Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program
PHILADELPHIA, April 08, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics, a clinical-stage women’s oncology company developing advanced small molecule and immunotherapy...